The clinical AI market is exploding. Governance is not optional.
The global healthcare AI market is projected to reach $187.95 billion by 2030, growing at 37% CAGR. But governance, the infrastructure that makes clinical AI safe, auditable, and legally defensible, is an almost entirely unoccupied category.
Why legacy systems struggle in the AI era
The dominant US electronic health record systems were architected long before modern AI existed. They were designed primarily for billing and documentation, not for overseeing autonomous AI decisions. That structural mismatch is the opportunity Open C is built to address.
Industry-wide challenges Open C is designed to solve:
- AI-driven security pressure. Modern attack tooling is becoming more adaptive against legacy hospital systems, which often lack native cryptographic attestation for AI outputs.
- Patient data crossing ungoverned boundaries. As clinical AI tools call out to external models, patient data can leave hospital control without a receipt, audit trail, or revocable consent record.
- Talent and maintenance pressure. Many legacy clinical platforms rely on programming environments with shrinking engineering talent pools and growing technical debt.
- No native governance primitives. Receipts, fail-closed gates, and tamper-evident ledgers are not native concepts in legacy clinical systems. They have to be architected in from the ground up.
Open C is built as a governance-first platform: receipts, attestation, and auditability are first-class architectural primitives, not bolt-ons. Pending regulation (the EU AI Act, FDA Predetermined Change Control Plans, and emerging state-level AI accountability rules) is moving the entire industry toward this model.
Market Sizing
TAM (Total Addressable Market): $47.6 billion in clinical AI by 2028, plus the $38 billion US EHR market currently served by legacy vendors. Both converge once governance becomes a regulatory requirement.
SAM (Serviceable Addressable Market): $12.1 billion. US health systems that cannot legally or safely continue operating on legacy EHR architecture once AI governance becomes a regulatory requirement.
SOM (Serviceable Obtainable Market): $410 million initial beachhead. Community health centers, rural clinics, and mid-size hospital networks underserved by the dominant EHR vendors, plus direct licensing to clinical AI companies that need governance infrastructure we cover in our patent portfolio.
The legacy EHR landscape was not designed for AI governance.
Roughly 65% of US hospital EHR market share sits with platforms architected decades before modern AI existed. AI is being added on top of those architectures, not built into them. Open C is built into the architecture from day one.
The structural gap in legacy clinical platforms
Architected for documentation, not for overseeing AI. The dominant clinical platforms were designed primarily for billing and recordkeeping. AI features are being layered on top of architectures that have no native concept of a cryptographic receipt, a fail-closed gate, or an independent governance attestation.
AI capabilities are being added rapidly. Major EHR vendors are rolling out generative AI features across documentation, clinical decision support, and patient communication. The pace of feature release is outrunning the pace of governance investment industry-wide.
Track record of AI tools that need stronger oversight. Multiple AI tools deployed inside legacy clinical platforms have later been shown by peer-reviewed research to underperform their vendor-reported accuracy. The pattern is consistent: AI capability is being released before independent validation infrastructure exists.
Why the second-largest EHR vendor faces similar pressure
Integration headwinds. The second-largest US clinical platform vendor has reported integration challenges and shifting market share over recent years.
Public-sector deployment delays. Major government deployments of legacy clinical platforms have been paused, restructured, or canceled in multiple countries over the past several years.
Strategic uncertainty. Industry analysts have publicly discussed the strategic direction of large legacy clinical platforms as their parent companies reallocate capital toward AI infrastructure investments.
Epic and Oracle built billing platforms in 1979 and 1984. They are working to retrofit governance, security, and AI auditability into architectures that were not designed for it. As regulation tightens and clinical AI scales, the market will need platforms built for the AI era. That is the opportunity Open C is built to serve.
Clinical AI is not a software feature. It is a medical decision.
When AI gets healthcare wrong, the cost falls on patients, providers, and the systems that serve them. Across the industry, regulators, courts, and clinicians are converging on the same question: when an AI tool acts inside a clinical workflow, can anyone prove what it did, what it relied on, and under whose authority?
Today, in most deployments, the honest answer is no. There is no receipt. That is the problem Open C is built to solve.
Three industry pressures converging
- Regulatory pressure. The EU AI Act, FDA AI/ML guidance, ONC HTI-1 and HTI-2 rules, CMS prior-authorization transparency requirements, and emerging state-level AI accountability laws are converging toward a single expectation: AI in healthcare must be auditable.
- Litigation pressure. Active litigation across the country involves AI-driven clinical and coverage decisions. The common evidentiary question across these cases is the same one Open C is built to answer: what exactly did the AI do, and can we prove it?
- Malpractice and liability pressure. Industry surveys show a steady rise in malpractice claims that involve AI tools. Clinicians and hospitals deploying AI are increasingly being asked to demonstrate that AI recommendations were independently validated by a human and recorded in an auditable way.
Every one of these pressures points the industry in the same direction: AI in healthcare needs receipts. That is the gap Open C was built to close.
A portfolio with depth. Every layer of clinical AI, governed.
Open C's intellectual property covers the full stack of governed clinical AI, from the moment a clinician speaks to the moment an insurer adjudicates the claim. No one can build ungoverned clinical AI at scale without crossing this portfolio.
Three revenue streams. One governance platform.
Open C generates revenue through SaaS subscriptions, licensing to EHR vendors and AI companies, and per-transaction governance fees. The IP portfolio creates both a defensive moat and an offensive licensing position.
Platform SaaS
Per-provider monthly subscription for the governed clinical AI platform. Tiered pricing from solo practitioners to large health systems. Includes the Fab 5 product suite: Echo (listening agent), CEE (clinical reasoning copilot), Alexandria (knowledge library), Living EHR (dynamic patient record), and Scribe (ambient documentation) with graduated autonomy levels.
Governance Licensing
License the governance infrastructure to EHR vendors, clinical AI startups, and health IT companies. Any company building clinical AI needs governance, and building it from scratch takes years. We license it in months.
IP Portfolio Licensing & Defense
A substantial portfolio of patent applications covering every layer of governed clinical AI, from ambient documentation to insurance adjudication. Portfolio valuation: undisclosed. Design-around cost for competitors: significant design-around investment. Any company deploying ungoverned clinical AI at scale will cross this portfolio. Exact filing counts and claim-level detail available to qualified investors under NDA.
Year 2 Corporate Structure
Open C is structured for a Year 2 split into three entities: (1) the platform company operating the SaaS product, (2) the IP holding company managing the patent portfolio and licensing, and (3) the research entity continuing governance innovation. This structure maximizes optionality for investors while protecting the IP moat.
Built at the bedside, not in a boardroom.
I started Open C Health Systems because I believe that artificial intelligence has the power to transform healthcare, but only if it is built the right way. Built with governance. Built with safety. Built with the clinician and the patient at the center, not the billing code.Aaron R. Seagle, Founder
Open C was created by a double board-certified nurse practitioner with over a decade of frontline clinical experience in Appalachian healthcare, completing a Doctor of Nursing Practice at South College focused on AI-assisted clinical decision support.
During a patient transfer, three medications vanished during an electronic handoff. An adverse reaction was silently converted to an allergy. An AI-generated summary contained a factual error with no provenance. That night, lying awake staring at the ceiling, the architecture began taking shape.
A substantial portfolio of provisional patent applications. A clinical AI platform built by a practicing clinician. This was not designed in a tech lab. It was designed by someone who has lived the problems it solves.
Round details, valuation, terms, and full diligence materials are shared after a brief intake. Open C Health Systems is a Delaware C-Corporation in active fundraising. Investor materials are made available only to accredited investors as defined under Rule 501 of Regulation D.
Open C Health Systems, Inc. · Delaware C-Corporation · Gerrardstown, WV
For non-investor inquiries: aaronseagle@openc.health